Mutual benefit: Patient-centricity in clinical trials
Uli Broedl and Bronwyn Lewis share what they learnt from a successful patient organization collaboration on clinical trial design.
Search
MORE GREEN: Reducing emissions throughout the supply chain
How Thermo Fisher is contributing to the decarbonization of Boehringer Ingelheim’s supply chain by reducing their own emissions
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
Soaring to save lives
Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Classical Swine Fever live vaccine approved in China
Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Positive opinion Ingelvac CircoFLEX and Ingelvac PRRSFLEX EU
Boehringer Ingelheim receives positive opinion for the combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU® in the EU
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Life forward - Boehringer Ingelheim company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Purevax range now available in 0.5 ml presentation
Boehringer Ingelheim announces reduced volume 0.5 ml Purevax vaccines for cats, more convenient vaccination experience combined with same efficacy
Jean-Michel Boers Appointed to PhRMA Board of Directors
Jean-Michel Boers Appointed to PhRMA Board of Directors
New digital Tx collab with Click
New digital therapy collaboration with Click Tx
Closing healthcare gaps with continued vaccination campaigns
How we continue combating rabies through collaborative efforts and the use of drone delivery in rural Kenya.
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
Supporting local communities by offsetting carbon emissions
Boehringer Ingelheim partially offsets its carbon emissions by partnering with ClimateSeed
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Update Israel and Gaza conflict
Update on Israel and the Palestine territories
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.